Table 3.
PPV and NPV for reference groups.
| Model | Cutoff | General | BRCAm | <50 | 50–64 | >65 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PPV | NPV | PPV | NPV | PPV | NPV | PPV | NPV | PPV | NPV | |||
| CA125 | Sp 0.95 | Se0.76 | 0.16% | 99.997% | 8.94% | 99.837% | 0.06% | 99.999% | 0.33% | 99.994% | 0.57% | 99.991% |
| Sp 0.99 | Se0.62 | 0.66% | 99.996% | 28.60% | 99.753% | 0.24% | 99.999% | 1.33% | 99.992% | 2.27% | 99.986% | |
| Se0.95 | Sp 0.53 | 0.02% | 99.999% | 1.29% | 99.939% | 0.01% | 100.000% | 0.04% | 99.998% | 0.08% | 99.996% | |
| Se0.99 | Sp 0.18 | 0.01% | 99.999% | 0.77% | 99.964% | 0.00% | 100.000% | 0.03% | 99.999% | 0.05% | 99.998% | |
| Youden | 0.11% | 99.998% | 6.35% | 99.888% | 0.04% | 99.999% | 0.23% | 99.996% | 0.39% | 99.993% | ||
| BARD1 CV validation set average |
Sp 0.95 | Se0.57 | 0.12% | 99.995% | 6.86% | 99.708% | 0.04% | 99.998% | 0.25% | 99.990% | 0.43% | 99.983% |
| Sp 0.99 | Se0.34 | 0.36% | 99.993% | 18.01% | 99.571% | 0.13% | 99.997% | 0.74% | 99.985% | 1.26% | 99.975% | |
| Se0.95 | Sp 0.5 | 0.02% | 99.999% | 1.21% | 99.935% | 0.01% | 100.000% | 0.04% | 99.998% | 0.07% | 99.996% | |
| Se0.99 | Sp 0.14 | 0.01% | 99.999% | 0.74% | 99.954% | 0.00% | 100.000% | 0.03% | 99.998% | 0.04% | 99.997% | |
| Youden | 0.04% | 99.998% | 2.52% | 99.869% | 0.02% | 99.999% | 0.09% | 99.996% | 0.15% | 99.992% | ||
| BARD1-CA125 CV validation set average |
Sp 0.95 | Se0.86 | 0.18% | 99.998% | 10.00% | 99.905% | 0.07% | 99.999% | 0.37% | 99.997% | 0.64% | 99.994% |
| Sp 0.99 | Se0.74 | 0.79% | 99.997% | 32.35% | 99.831% | 0.28% | 99.999% | 1.59% | 99.994% | 2.70% | 99.990% | |
| Se0.95 | Sp 0.78 | 0.05% | 99.999% | 2.71% | 99.959% | 0.02% | 100.000% | 0.09% | 99.999% | 0.16% | 99.998% | |
| Se0.99 | Sp 0.25 | 0.01% | 100.000% | 0.85% | 99.974% | 0.01% | 100.000% | 0.03% | 99.999% | 0.05% | 99.998% | |
| Youden | 0.13% | 99.999% | 7.51% | 99.917% | 0.05% | 100.000% | 0.27% | 99.997% | 0.47% | 99.995% | ||
PPV, positive predictive value; NPV, negative predictive value; Se, sensitivity; Sp, specificity; BRCAm, BRCA1/2 mutation carriers; <50, 50–64, >50, women less than 50, between 50–64, or more than 50 years of age.